E-commerce giants Amazon and Flipkart had been served show-cause notice together with 20 other on-line sellers by the Drugs Controller General of India (DCGI) concerning the sale of drugs without a licence.
The show-cause notice dated February 8 by DCGI V G Somani cited a Delhi High Court order dated December 12, 2018, which prohibits on-line gross sales of medicines without a licence. The notice said that the DCGI had forwarded the order to all state and Union Territories in May and November 2019 and once more on February 3 for mandatory motion and compliance.
“In spite of the same, you are found to be engaged in such activities without a licence,” the notice to the web drugs sellers mentioned. “You are hereby asked to show cause within 2 days from the date of issue of this notice, why action shall not be taken against you for sale, or stock, or exhibit or offer for sale or distribution of drugs in contravention of the provisions of the Drugs and Cosmetics Act 1940 and rules made thereunder,” the notice mentioned.
ALSO READ | Amazon begins one other spherical of layoffs, 18,000 staff to be affected
The notice states that the sale or inventory or exhibit or supply for sale or distribution of any drug requires a licence from the involved state licensing authority and circumstances of a licence are required to be complied with by the licence holders. The DCGI has mentioned that in case of no reply, will probably be presumed that the corporate has nothing to say within the matter and mandatory motion will likely be initiated in opposition to them without any additional notice.
When contacted, Flipkart Health Plus mentioned that it’s a digital healthcare market platform that permits straightforward and handy entry to real and inexpensive medicines and healthcare merchandise, from unbiased sellers, for hundreds of thousands of prospects throughout the nation. “We have received the notice from CDSCO (Central Drugs Standard Control Organisation) and are responding to it appropriately. As an organisation, we remain committed to complying with the laws of the land and towards continuous improvements of our processes/checks and controls on our marketplace platform to build trust and enhance customer experience,” Flipkart Health plus mentioned.
Email queries searching for feedback over the event despatched to Amazon India and others didn’t elicit any reply. Traders physique Confederation of All India Traders (CAIT) National President BC Bhartia and Secretary General Praveen Khandelwal in a joint assertion demanded the federal government to strictly implement the legislation and the judgment of the Delhi excessive court docket and be certain that no e-commerce firm is promoting drugs violating the Drug and Cosmetic Act.
“Government must take strict action against the e-commerce, e-pharma intermediaries, marketplace platforms including Amazon and Flipkart who are selling the medicine without obtaining the requisite license-added the trade leaders,” the assertion mentioned. CAIT added that a number of on-line drugs sellers are foreign-controlled and subsequently, are ineligible to search these retail licences as this is able to be a violation of the extant Foreign Direct Investment coverage within the multi-brand retail sector or inventory-based e-commerce.
ALSO READ | Amazon India publicizes new provides on 5G smartphones
